Treatment options for patients with hormone-dependent ER+ breast cancers are estrogen antagonist such as tamoxifen, estrogen receptor down regulator such as Fulvestrant or inhibitors of estrogen biosynthesis such as aromatase inhibitors [6,7]. Here, CYP19A1 is linked to breast carcinoma.